Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

37.50
-2.6900-6.69%
Post-market: 37.700.2000+0.53%18:00 EDT
Volume:2.50M
Turnover:96.21M
Market Cap:4.44B
PE:-7.12
High:41.08
Open:40.28
Low:37.46
Close:40.19
Loading ...

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Zacks
·
24 Jan

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga
·
23 Jan

Stifel Nicolaus Initiates Coverage on Cytokinetics With Buy Rating, $80 Price Target

MT Newswires Live
·
22 Jan

Cytokinetics Initiated at Buy by Stifel

Dow Jones
·
22 Jan

Cytokinetics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $80

THOMSON REUTERS
·
22 Jan

Cytokinetics initiated with a Buy at Stifel

TIPRANKS
·
22 Jan

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Jan

Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise

TIPRANKS
·
21 Jan

Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586

TIPRANKS
·
21 Jan

Cytokinetics Announces Start of Amber-Hfpef, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

THOMSON REUTERS
·
21 Jan

Truist Financial Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
14 Jan

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Cytokinetics: Promising Drug Pipeline and Strategic Vision Drive Buy Rating

TIPRANKS
·
14 Jan

Cytokinetics’ Promising Future: Aficamten Approval and Robust Pipeline Drive Growth Prospects

TIPRANKS
·
14 Jan

Cautious Hold on Cytokinetics Amid Regulatory Uncertainties and Distant Milestones

TIPRANKS
·
14 Jan

Cytokinetics CEO not looking to be bought, but would listen, STAT says

TIPRANKS
·
14 Jan